| ［1］Kaufmann SH. How can immunology contribute to the control of tuberculosis? Nat Rev Immunol, 2001, 1(1): 20-30.［2］Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ, 2003, 10(1): 45-65.［3］Black RA, Rauch CT, Kozlosky CJ, et al. A metalloprotei-nase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature, 1997, 385(6618): 729-733.［4］Grell M, Douni E, Wajant H, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell, 1995, 83(5): 793-802.［5］Mootoo A, Stylianou E, Arias MA, et al. TNF-alpha in tuberculosis: a cytokine with a split personality（Review）.Inflamm Allergy Drug Targets, 2009, 8(1): 53-62.［6］North RJ, Jung YJ. Immunity to tuberculosis（Review）. Annu Rev Immunol, 2004, 22: 599-623.［7］Girardi E, Raviglione MC, Antonucci G, et al. Impact of the HIV epidemic on the spread of other diseases: the case of tuberculosis. AIDS, 2000, 14 Suppl 3: S47-S56.［8］Whalen C, Horsburgh CR Jr, Hom D, et al. Site of disease and opportunistic infection predict survival in HIV-associated tuberculosis. AIDS, 1997, 11(4): 455-460.［9］Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis, 2008, 8(10): 601-611.［10］Flynn JL， Chan J. Immunology of tuberculosis. Annu Rev Immunol, 2001, 19: 93-129.［11］解元元，朱朝敏. 趋化因子在抗结核免疫中的作用. 中华结核和呼吸杂志, 2008, 31(11): 844-846.［12］Algood HM, Chan J, Flynn JL. Chemokines and tuberculosis. Cytokine Growth Factor Rev, 2003, 14(6): 467-477.［13］Harris J, Hope JC, Keane J. Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis. J Infect Dis, 2008, 198(12): 1842-1850.［14］Bekker LG, Moreira AL, Bergtold A, et al. Immunopathologic effects of tumor necrosis factor alpha in murine mycobacterial infection are dose dependent. Infect Immun, 2000, 68(12): 〖JP〗6954-6961.［15］Schulze-Osthoff K, Ferrari D, Los M, et al. Apoptosis signaling by death receptors. Eur J Biochem, 1998, 254(3): 439-459.［16］Schaible UE, Winau F, Sieling PA, et al. Apoptosis facilitates antigen presentation to T lymphocytes through MHCI and CD1 in tuberculosis. Nat Med, 2003, 9(8): 1039-1046.［17］Balcewicz-Sablinska MK, Keane J, Kornfeld H, et al. Pathogenic Mycobacterium tuberculosis evades apoptosis of host macrophages by release of TNF-R2, resulting in inactivation of TNF-alpha. J Immunol, 1998, 161(5): 2636-2641.［18］Cosma CL, Sherman DR, Ramakrishnan L. The secret lives of the pathogenic mycobacteria. Annu Rev Microbiol, 2003, 57: 641-676.［19］Roach DR, Briscoe H, Baumgart K, et al.Tumor necrosis factor (TNF) and a TNF-mimetic peptide modulate the granulomatous response to Mycobacterium bovis BCG infection in vivo. Infect Immun, 1999, 67(10): 5473-5476.［20］Kindler V, Sappino AP, Grau GE, et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell, 1989, 56(5): 731-740.［21］Bean AG, Roach DR, Briscoe H, et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol, 1999, 162(6): 3504-3511.［22］Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity, 1995, 2(6): 561-572.［23］Mohan VP,. Scanga CA, Yu K, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun, 2001, 69(3): 1847-1855.［24］Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med, 2001, 345(15): 1098-1104.［25］Zganiacz A, Santosuosso M, Wang J, et al. TNF-alpha is a critical negative regulator of type 1 immune activation during intracellular bacterial infection. J Clin Invest, 2004, 113(3): 401-413.［26］Fremond C, Allie N, Dambuza I, et al. Membrane TNF confers protection to acute mycobacterial infection. Respir Res, 2005, 6: 136.［27］Küpeli E, Karnak D, Beder S, et al. Diagnostic accuracy of cytokine levels (TNF-alpha, IL-2 and IFN-gamma) in bronchoalveolar lavage fluid of smear-negative pulmonary tuberculosis patients. Respiration, 2008, 75(1): 73-78.［28］Price NM, Gilman RH, Uddin J, et al. Unopposed matrix metalloproteinase-9 expression in human tuberculous granuloma and the role of TNF-alpha dependent monocyte networks. J Immunol, 2003, 171(10): 5579-5586.［29］Kim EM, Uhm WS, Bae SC, et al. Incidence of tuberculosis among korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers. J Rheumatol, 2011, 38(10): 2218-2223.［30］Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum, 2009, 60(7): 1884-1894.［31］Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis, 2010, 69(3): 522-528.［32］Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther, 2002, 301(2): 418-426.［33］Mandic D, Curcic R, Radosavljevic G, et al. Recommendations for tuberculosis screening before and during treatment with tumour necrosis factor inhibitors. Srp Arh Celok Lek, 2009, 137(3-4): 211-216.［34］Eum SY, Lee YJ, Min JH, et al. Association of antigen-stimulated release of tumor necrosis factor-alpha in whole blood with response to chemotherapy in patients with pulmonary multidrug-resistant tuberculosis. Respiration, 2010, 80(4): 275-284.［35］Mattos AM, Almeida Cde S, Franken KL, et al. Increased IgG1, IFN-gamma, TNF-alpha and IL-6 responses to Mycobacterium tuberculosis antigens in patients with tuberculosis are lower after chemotherapy. Int Immunol, 2010, 22(9): 775-782.［36］Sutherland JS, de Jong BC, Jeffries DJ, et al. Production of TNF-alpha, IL-12(p40) and IL-17 can discriminate between active TB disease and latent infection in a West African cohort. PLoS One, 2010, 5(8): e12365.［37］Su WL, Perng WC, Huang CH, et al. Association of reduced tumor necrosis factor alpha, gamma interferon, and interleukin-1beta (IL-1beta) but increased IL-10 expression with improved chest radiography in patients with pulmonary tuberculosis. Clin Vaccine Immunol, 2010, 17(2): 223-231.［38］杨颖乔，彭圣威. 肺结核患者细胞因子水平测定的临床研究. 咸宁学院学报（医学版）, 2009, 23(3): 211-212.［39］Eum SY, Jeon BY, Min JH, et al. Tumor necrosis factor-alpha and interleukin-10 in whole blood is associated with disease progression in pulmonary multidrug-resistant tuberculosis patients. Respiration, 2008, 76(3): 331-337.［40］Lee JS, Song CH, Lim JH, et al. The production of tumour necrosis factor-alpha is decreased in peripheral blood mononuclear cells from multidrug-resistant tuberculosis patients following stimulation with the 30 kDa antigen of Mycobacterium tuberculosis. Clin Exp Immunol, 2003, 132(3): 443-449.［41］de Castro Cunha RM, Kallas EG, Rodrigues DS, et al.Interferon-gamma and tumour necrosis factor-alpha production by CD4+ T and CD8+ T lymphocytes in AIDS patients with tuberculosis. Clin Exp Immunol, 2005, 140(3): 491-497.［42］Nagesh Babu G, Kumar A, Kalita J et al. Proinflammatory cytokine levels in the serum and cerebrospinal fluid of tuberculous meningitis patients. Neurosci Lett, 2008, 436(1): 48-51.［43］谢育琴，张锦宏，谢丽兰. 胸腔积液肿瘤坏死因子-α检测对结核性胸膜炎与肺癌鉴别诊断的意义. 中国防痨杂志, 2011, 33(7): 422-424.［44］Rubin EJ. The granuloma in tuberculosis—friend or foe? N Engl J Med, 2009, 360(23): 2471-2473.［45］Tsenova L, Sokol K, Freedman VH, et al. A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death. J Infect Dis, 1998, 177(6): 1563-1572.［46］Wallis RS, Kyambadde P, Johnson JL, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS, 2004, 18(2): 257-264.［47］Wallis RS, van Vuuren C,Potgieter S. Adalimumab treatment of life threatening tuberculosis. Clin Infect Dis, 2009, 48(10): 1429-1432.［48］Shen H, Wang C, Yang E, et al. Novel recombinant BCG coexpressing Ag85B, ESAT-6 and mouse TNF-alpha induces significantly enhanced cellular immune and antibody responses in C57BL/6 mice. Microbiol Immunol, 2010, 54(8): 435-441. |
京公网安备11010202007215号
Total visitors: Visitors of today: Now online:
This work is licensed under Creative Commons Attribution 3.0 License.
